Neogen Corporation, a global provider of food and animal safety solutions, has announced a definitive agreement to sell its global genomics business to animal health giant Zoetis Inc. The transaction, valued at $160 million (subject to customary closing adjustments), marks a significant step in Neogen's ongoing portfolio optimisation strategy.
The divestiture allows Neogen to streamline its operational footprint, redirecting capital and focus toward its core competitive advantages in the food and animal safety markets.
Deleveraging and Portfolio Simplification
For Neogen, the sale serves as a primary financial lever for debt reduction. The company confirmed that the net proceeds from the $160 million transaction will be utilised primarily to accelerate deleveraging efforts and improve long-term profitability margins.
Mike Nassif, Chief Executive Officer and President of Neogen, framed the sale as a critical component of the company's broader corporate realignment.
"This transaction is part of the company's strategic portfolio review and allows the company to accelerate de-leveraging and improve profitability going forward," Nassif stated. "Furthermore, this deal allows us to focus in areas where the company has the most significant competitive advantage and further leverage our core capabilities in food and animal safety."
The GeneSeek® Portfolio
The sale involves Neogen's entire genomics unit, widely known under the GeneSeek® banner. The division is recognised as a pioneer in advanced DNA testing for both the livestock and companion animal industries, providing data-driven insights to improve herd health, trait screening, and overall profitability in the beef and dairy sectors.
Key Assets Transferred to Zoetis:
Igenity® and GGP® Portfolios: Industry-standard genomic prediction tools.
Encompass™ Platform: The division's proprietary platform for genomic data integration.
Traceability Partnerships: Strategic initiatives advancing DNA-backed animal traceability.
The genomics unit is a substantial operational asset, having generated approximately $90 million in sales during Neogen's 2025 fiscal year.
Timeline and Transition
The transaction is expected to close by the end of the first half of Neogen’s 2027 fiscal year, pending standard regulatory approvals and closing conditions. Until the deal concludes, Neogen has committed to maintaining a "smooth transition" for existing customers, employees, and stakeholders to ensure continuity of testing services.
Guggenheim Securities LLC served as the exclusive financial advisor to Neogen for the transaction.
.png)
